HMPL-760 planned dose 1

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

2mo

HCMPhase 2$2.3B

HMPL-760 planned dose 1 Phase 2 Results Expected

HMPL-760 planned dose 1• Relapsed/Refractory Diffuse Large B-Cell Lymphoma61

May 12Estimated

00%

Competitive Landscape

0 competitors in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Drug Information

Target Indication

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical Trial

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

HCM

Hutchmed

Related Pipeline

Acute Myeloid Leukemia

Metastatic Pancreatic Cancer

Advanced Renal Cell Carcinoma

Advanced Intrahepatic Cholangiocarcinoma

Advanced Endometrial Cancer